Patents by Inventor Julian Davis
Julian Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9201074Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof, that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.Type: GrantFiled: September 13, 2012Date of Patent: December 1, 2015Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu
-
Publication number: 20150266954Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.Type: ApplicationFiled: March 13, 2015Publication date: September 24, 2015Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
-
Publication number: 20150118238Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to the extracellular domain of human c-Met, compositions and kits comprising such c-Met antibodies, or antigen-binding fragments thereof, and methods of using the same for detection of human c-Met that aid in identifying patients with tumors expressing or overexpressing human Met and/or improving their treatment response with anti-c-Met therapeutics.Type: ApplicationFiled: May 1, 2013Publication date: April 30, 2015Inventors: Gregory Beuerlein, Julian Davies, Irene Jennifer Denning, Ling Liu, Jirong Lu, Peter Edward Vaillancourt
-
Publication number: 20150042486Abstract: A communication arrangement for a subsea well control system, comprising an umbilical between a topside location and a subsea location, an electrical conductor in said umbilical, and a data transmission system configured to transmit and receive data between said locations via said conductor, wherein a return path for said data comprises the sea.Type: ApplicationFiled: January 22, 2013Publication date: February 12, 2015Applicant: Vetco Gray Controls LimitedInventors: Silviu Puchianu, Graham Morley, Andrew Packham, Hilton Smart, Julian Davis
-
Publication number: 20140349310Abstract: Provided is a monoclonal antibody, or antigen-binding fragment thereof that binds to c-Met. Such antibodies, or antigen-binding fragments thereof, are useful in in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting cell surface c-Met receptor levels for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients harboring tumors in which c-Met is implicated in pathogenesis.Type: ApplicationFiled: September 13, 2012Publication date: November 27, 2014Applicant: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu
-
Patent number: 8692686Abstract: An electronics module for a well installation configured to receive software via a wireless connection and methods of installing software on an electronics module for a well installation, are provided. An example of such electronics module comprises a short-range wireless receiver for wirelessly receiving software and/or data from an external wireless source. Modem external interface wiring can be employed as an antenna for the wireless receiver to receive the wireless transmission of the software and/or data.Type: GrantFiled: July 8, 2008Date of Patent: April 8, 2014Assignee: Vetco Gray Controls LimitedInventors: Julian Davis, Ian Kent, Robert Dalziel
-
Patent number: 8623365Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: December 21, 2011Date of Patent: January 7, 2014Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20130273071Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Patent number: 8530414Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: GrantFiled: September 12, 2012Date of Patent: September 10, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Patent number: 8481037Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: GrantFiled: January 14, 2011Date of Patent: July 9, 2013Assignee: MedImmune, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry Watkins
-
Publication number: 20130071405Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: ELI LILLY AND COMPANYInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Patent number: 8398974Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: GrantFiled: June 25, 2012Date of Patent: March 19, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Publication number: 20120263723Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: ApplicationFiled: June 25, 2012Publication date: October 18, 2012Applicant: ELI LILLY AND COMPANYInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Publication number: 20120212230Abstract: A method of testing a solenoid of a directional control valve in a subsea hydrocarbon production system, the solenoid having a coil and an armature for operating the valve and the coil being energized by a drive voltage across it, the method comprises removing or reducing the drive voltage and sensing current through the coil to produce an indication of movement of the armature.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Inventors: Julian Davis, Martin Stokes
-
Patent number: 8217148Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.Type: GrantFiled: November 18, 2009Date of Patent: July 10, 2012Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
-
Publication number: 20120109097Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: January 14, 2011Publication date: May 3, 2012Applicant: MEDIMMUNE, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Publication number: 20120072335Abstract: Systems, and programming for improved arrangement and administration of syndicated loans using computer networks. Each of a plurality of bookrunners is authorized to invite any number of other bookrunners, as well as any number of loan participants, or underwriters (i.e. investors or lenders), to participate in offering and administering a loan, typically by providing various forms of information describing the proposed loan, including the borrower, the proposed terms, and possibly any potential participants in making the loan. Invitees who accept such invitations may be associated with the inviting bookrunner, and upon being accepted as participants may be granted by the bookrunner access to various sets of communications, documents, and other information concerning the proposed loan.Type: ApplicationFiled: March 25, 2011Publication date: March 22, 2012Applicant: Debtdomain GLMS Pte Ltd.Inventors: Sean Yat Sing Tai, Timothy Julian Davis Skinner
-
Patent number: 8128927Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.Type: GrantFiled: October 15, 2009Date of Patent: March 6, 2012Assignee: Eli Lilly and CompanyInventors: Julian Davies, Craig Duane Dickinson, David Matthew Marquis, Ying Tang, Peter Edward Vaillancourt
-
Patent number: 8105597Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: July 17, 2009Date of Patent: January 31, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins